Analyzing Baird Medical Investment (NASDAQ:BDMD) & Artivion (NYSE:AORT)

Baird Medical Investment (NASDAQ:BDMD) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Profitability

This table compares Baird Medical Investment and Artivion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
Artivion	2.55%	7.15%	3.63%

Risk & Volatility

Baird Medical Investment has a beta of -1.18, meaning that its stock price is 218% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Earnings & Valuation

This table compares Baird Medical Investment and Artivion”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	$22.54 million	3.07	N/A	N/A	N/A
Artivion	$458.69 million	2.43	$9.77 million	$0.24	95.50

Artivion has higher revenue and earnings than Baird Medical Investment.

Insider & Institutional Ownership

19.8% of Baird Medical Investment shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 78.9% of Baird Medical Investment shares are owned by company insiders. Comparatively, 6.3% of Artivion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Baird Medical Investment and Artivion, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	1	0	0	0	1.00
Artivion	0	1	7	0	2.88

Artivion has a consensus price target of $47.83, suggesting a potential upside of 108.69%. Given Artivion’s stronger consensus rating and higher probable upside, analysts plainly believe Artivion is more favorable than Baird Medical Investment.

Summary

Artivion beats Baird Medical Investment on 9 of the 11 factors compared between the two stocks.

About Baird Medical Investment

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.

About Artivion

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.